Vyvron Review: Thirteen Charges a Year, Not Twelve

Vyvron (vyvron.com) is a new operator selling compounded GLP-1, a microdosing program and three injectable longevity products. We benched it in August 2026, and two things about its pricing are not what the page says they are. Both change the number you would actually pay, and both survive multiplication badly.¹

Finding one: the month that is four weeks long

Vyvron's own fine print reads that you are charged $199 per four weeks, billed every four weeks, auto-renewing until you cancel. Elsewhere on the same site, the same plan renders as "$199/mo" and "starting at $199/mo".

A four-week cycle bills thirteen times in a 52-week year. Twelve months bills twelve. At the $199 rung the difference is $2,587 a year against the $2,388 that "$199/mo" implies — an extra $199 nobody put in the headline, and one full extra medication shipment you did not budget for.

This is a labeling error rather than a hidden fee: the cadence is disclosed, just not in the same sentence as the price. It is also the exact failure mode our cost calculator exists to catch, because the fix is arithmetic, not vigilance. Run any four-weekly plan as thirteen cycles, always.

Finding two: there is no monthly tirzepatide plan

Vyvron's weight-loss page shows three tiers that look like three monthly prices. They are not three prices of the same kind.

The Start tier is $199 per four weeks, billed every four weeks. It is semaglutide only, and it is the only genuinely recurring rung on the site. The Transform tier, badged most popular, displays $285 a month and is charged as $790 once, covering twelve weeks of tirzepatide. The Premium tier displays $248 a month and is charged as $2,981 once, covering a full year.

So the smallest tirzepatide purchase Vyvron sells is $790 up front. There is no way to buy its tirzepatide for one month, at any price. We do not file a monthly tirzepatide figure for Vyvron at all, because substituting a prepay rung for a monthly one is how a provider ends up on a cheapest board at a price nobody can buy — and it is why Vyvron does not appear on our cheapest tirzepatide ranking.

The displayed $285 is also arithmetically inconsistent with the rest of the page. It divides $790 across roughly 2.77 calendar months. Divide the same $790 across three four-week cycles — the cadence Vyvron actually bills on — and it is $263. Two different definitions of "per month" are in use inside one pricing table.

The founding-rate framing

Vyvron advertises founding-member rates of $199 per four weeks for weight loss, $149 for microdosing and $189 for longevity, against post-founding list prices of $249, $179 and $229.

The homepage program cards do not agree with the program pages. The homepage shows microdosing at $179, which is the post-founding list price presented as if it were current, and longevity at $145, which is the cheapest single longevity product rather than the program rate. We take the program pages, because that is where the enrolment button and the billing disclosure live. Longevity products are priced individually: injectable NAD+ at $229, injectable sermorelin at $229 and injectable B12-MIC at $145.

The scarcity device is not a device. The counter reading "100 of 100 founding spots left" is a hardcoded constant behind a progress bar fixed at full width. It has never moved and it cannot.

What is genuinely good here

Clinical services run through OpenLoop Health — a real, substantial telehealth infrastructure company, named in the privacy policy rather than implied.

State disclosure is the best on this bench and deserves saying so plainly. Vyvron serves all 50 states plus DC, requires a video visit in Arkansas, DC, Delaware, Kansas, Mississippi, New Mexico, Rhode Island and West Virginia, and states that compounded GLP-1 is unavailable in Mississippi, where only branded product can be prescribed. Nobody else here discloses at that resolution — Auren Rx publishes no state list at all — and this is precisely the check that turns a good price into a usable one, as covered in our provider checklist.

What is missing

No pharmacy is named. No prescriber is named and no NPI is published, so nothing can be verified against the national provider registry.

You are charged when you complete the intake, before a provider reviews it. A full refund is available only if you cancel within 72 hours with no services rendered, or if a provider medically disqualifies you. Cancellation otherwise requires 72 hours' notice before the next billing date or you are charged for that cycle. Prepaid twelve-week and annual plans refund only the months whose medication has not shipped — which is a real exposure on a $2,981 charge.

Vyvron's testimonial section ships placeholders stating that patient stories will appear once written consent is obtained from founding members. That is honest, and it is also an unambiguous statement that this company has no track record yet.

The regulatory screen was clean. The trading name and its clinical partner both returned zero company-column matches in the FDA's live warning-letter index in August 2026, in a pass whose positive control correctly returned a known 2026 letter for an unrelated seller.² Worth keeping in proportion: a clean record on a company with no operating history is a weaker signal than the same record on an established one, because there has been less time for a problem to surface.

Where it lands on value

If you want semaglutide and you budget thirteen cycles rather than twelve, $199 per four weeks is a fair rung and the state disclosure behind it is the best here. If you want tirzepatide, the entry ticket is $790 with no monthly alternative, and Auren Rx at $299, Trellis Vitality at $199 and The Edit at $309 all sell one. If you want a provider with patients behind it, Vyvron says on its own site that it does not have them yet.

Price the semaglutide plan honestly — thirteen times $199 — against the cheapest semaglutide board, and read the sourced cost work in our research library.